PHILADELPHIA — (April 23, 2019) — After extensive peer review, The Wistar Institute’s Cancer Center has received an “exceptional” rating on its Cancer Center Support Grant (CCSG) application from t…
PHILADELPHIA — (April 18, 2019) — Wistar scientists have developed a novel synthetic DNA approach for patient-specific production of cancer-targeting molecules called bispecific T cell engagers. DN…
PHILADELPHIA — (April 17, 2019) — Wistar scientists have identified a critical regulator of the function of myeloid derived suppressive cells (MDSCs), opening new opportunities for specific therape…
PHILADELPHIA — (Apr. 5, 2019) — A new approach for delivery of DNA-encoded monoclonal antibodies (DMAbs) has been reported by Wistar scientists and their collaborators. This new technology allows d…
PHILADELPHIA — (March 6, 2019) — Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleos…
Philadelphia and San Jose, Calif. – (Feb. 21, 2019) – The Wistar Institute has extended its collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the b…
PHILADELPHIA — (Feb. 18, 2019) — Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release …
PHILADELPHIA — (Feb. 15, 2019) — David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center, and the W.W. Smith Charitable Trust Professor in Cancer Resear…
PHILADELPHIA — (Feb. 14, 2019) — The Wistar Institute was awarded two grants totaling more than $128,000 from the Pennsylvania Department of Labor & Industry to support the Institute’s training…
PHILADELPHIA and TAMPA, Fla. — (Feb. 14, 2019) — Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma mor…
